Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 11/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.41 |
| ▸ | WEE1 | P30291 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17958820 | 1.00 | STAT6 (0.54) | STAT6ADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL16570901 | 0.89 | STAT6 (0.63) | STAT6CDK4CCND1CDK6FGFR4 | |
| SCHEMBL17958809 | 0.82 | STAT6 (0.51) | STAT6ADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL16580878 | 0.82 | STAT6 (0.51) | STAT6ADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL17958750 | 0.82 | STAT6 (0.53) | STAT6ADRA2AADRA2BADRA2CFGFR4 | |
| SCHEMBL16570040 | 0.82 | STAT6 (0.53) | STAT6ADRA2AADRA2BADRA2CFGFR4 | |
| SCHEMBL16580727 | 0.82 | STAT6 (0.52) | STAT6ADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL16580921 | 0.81 | STAT6 (0.52) | STAT6ADRA2AADRA2BADRA2CCDK4 | |
| SCHEMBL16570396 | 0.81 | STAT6 (0.52) | STAT6ADRA2AADRA2BADRA2CFGFR4 | |
| SCHEMBL16580834 | 0.80 | FGFR4 (0.47) | STAT6CDK4FGFR4WEE1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | STAT6 103/4885ADRA2A 3261/4885ADRA2B 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.